Puma Biotechnology, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PBYI research report →
Price Chart
About the company
Puma Biotechnology, Inc. is a biopharmaceutical company dedicated to the global development and commercialization of treatments aimed at advancing cancer care. Its lead drug candidate, orally administered neratinib (PB272), targets a range of indications.
- CEO
- Alan H. Auerbach
- IPO
- 2012
- Employees
- 179
- HQ
- Los Angeles, CA, US
Get TickerSpark's AI analysis on PBYI
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $364.47M
- P/E
- 14.80
- Fwd P/E
- 17.20
- PEG
- -0.41
- P/S
- 1.57
- P/B
- 2.48
- EV/EBITDA
- 8.13
- Div Yield
- 0.00%
- Gross Margin
- 73.59%
- Op Margin
- 11.27%
- Net Margin
- 10.28%
- ROE
- 17.52%
- ROIC
- 14.63%
Latest fiscal year · YoY change
- Revenue
- $228.37M-0.9%
- Gross Profit
- $170.21M+2.5%
- Op Income
- $37.30M
- Net Income
- $31.11M+2.8%
- EPS
- $0.62+0.0%
- OCF Growth
- +7.4%
- FCF Growth
- +7.4%
- 52W High
- $11.50
- 52W Low
- $4.84
- 50D MA
- $9.54
- 200D MA
- $8.04
- Beta
- 1.21
- RSI (14)
- 24
- Avg Volume
- 387.40K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Puma posted modestly higher NERLYNX product revenue, stayed profitable, and raised full-year net income guidance despite lower royalty expectations from China.· November 5, 2026
- Total revenue was $55.1 million, with NERLYNX net product revenue of $54.1 million, up from $53.6 million in Q2 2026 and $51.9 million in Q3 2025.
- GAAP net income was $6.0 million, or $0.11 per diluted share; non-GAAP net income was $8.0 million, or $0.15 per basic and diluted share.
- Full-year 2026 net NERLYNX product revenue guidance was trimmed slightly to $205 million-$208 million, while full-year net income guidance was raised to $20 million-$22 million.
- Royalty revenue fell to $0.9 million from $2.9 million in Q2 because Puma recorded a $2.1 million cumulative reduction tied to China generic-share thresholds.
- Alisertib programs continued to advance, with updated ALISCA-Breast1 data expected at SABCS in December and additional lung data expected in 2027.
Puma reported third-quarter 2026 total revenue of $55.1 million. NERLYNX gross revenue was $75.1 million, net product revenue was $54.1 million, and royalty revenue was $0.9 million. GAAP net income was $6.0 million, or $0.11 per diluted share, versus $8.2 million, or $0.16 per share, in Q2 2026. Non-GAAP net income was $8.0 million, or $0.15 per basic and diluted share. Gross-to-net was about 28%, compared with 27.9% in Q2 2026. U.S. net sales of NERLYNX were $50.6 million, and product supply revenue to international partners was about $3.6 million. For full-year 2026, Puma now expects net NERLYNX product revenue of $205 million-$208 million, royalty revenue of $18 million-$19 million, no license revenue, gross-to-net of 27.5%-28%, and net income of $20 million-$22 million. For Q4 2026, it guided to net NERLYNX product revenue of $56 million-$58 million, royalty revenue of $11 million-$12 million, gross-to-net of approximately 28%-29%, and net income of $10 million-$12 million.
Alan Auerbach emphasized that Puma is focused on sustaining positive net income while managing the business carefully, and said the company believes 2026 will be the second straight year of U.S. demand growth for NERLYNX. He framed the quarter as evidence of commercial discipline and said the company would continue reducing expenses if needed to preserve profitability. On the pipeline side, he highlighted that ALISCA-Breast1 data appear supportive of a future phase III trial and that Puma plans to engage regulators in the first half of 2027.
Maximo Nougues said Q3 GAAP net income was $6.0 million and non-GAAP net income was $8.0 million, while SG&A was $16.3 million and R&D was $18.3 million. He noted cash and marketable securities of about $108.5 million at September 30, 2026, and said Puma is now debt-free after making its final $11.1 million principal loan payment in Q2. He also explained that the lower royalty revenue reflected a $2.1 million cumulative reduction tied to China market-share data, and that higher gross-to-net was mostly driven by higher Medicaid share. For 2026, he said R&D is expected to rise 28%-30% year over year while SG&A is expected to remain flat.
The call was mostly scripted with no live analyst Q&A included in the transcript, so there were no analyst challenges or follow-up questions to management. The most notable discussion points were management’s explanation for lower royalty revenue from China, the slightly lower full-year NERLYNX revenue outlook, and the updated alisertib timelines. Management also addressed tariffs, saying they do not currently expect a material impact on product cost or results, though policy changes remain hard to predict.
The quarter showed continued profitability, solid cash at $108.5 million, and no debt, giving Puma flexibility to keep funding NERLYNX and alisertib. Management also signaled confidence in the pipeline, saying ALISCA-Breast1 data support a potential phase III path and that more data readouts are coming in 2027.
NERLYNX royalty revenue stepped down sharply because of the China generic threshold, and full-year royalty guidance was cut to $18 million-$19 million from $20 million-$23 million. NERLYNX demand softened quarter over quarter, with commercial new patient starts down 13% and total prescriptions down 5%, while higher gross-to-net pressure from Medicaid also weighed on the outlook.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 77.6%
- Shares Outstanding
- 51.70M
- Float Shares
- 40.14M
of shares held by institutions
166 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for PBYI, newest first.
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 4.21M | ▲ 402.44K |
| Acorn Capital Advisors, LLC | 4.13M | 0 |
| Vanguard Group Inc | 3.80M | ▲ 106.03K |
| American Century Companies Inc | 2.74M | ▲ 422.66K |
| Acadian Asset Management LLC | 2.08M | ▲ 30.57K |
| Lsv Asset Management | 1.94M | ▲ 323.12K |
| Vanguard Portfolio Management LLC | 1.89M | ▲ 67.68K |
| Renaissance Technologies LLC | 1.88M | ▲ 47.80K |
| Vanguard Capital Management LLC | 1.85M | ▲ 13.14K |
| Dimensional Fund Advisors LP | 1.56M | ▲ 37.72K |
| Geode Capital Management, LLC | 1.33M | ▼ 6.65K |
| O'Shaughnessy Asset Management, LLC | 1.11M | ▼ 12.69K |
Held by 173 ETFs
Biggest fund positions in PBYI by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 11, 26 | MILLER MICHAEL PATRICK | sell | 15,000 |
| Sep 14, 26 | WILSON TROY EDWARD | sell | 5,000 |
| Sep 14, 26 | Cesano Alessandra | other | 50,000 |
| Sep 14, 26 | Cesano Alessandra | sell | 62,150 |
| Sep 14, 26 | Cesano Alessandra | other | 50,000 |
| Jul 6, 26 | AUERBACH ALAN H | sell | 44,058 |
| Jul 6, 26 | HUNT DOUGLAS M | sell | 8,460 |
| Jul 6, 26 | NOUGUES MAXIMO F | sell | 9,386 |
| Jun 11, 26 | WILSON TROY EDWARD | other | 27,000 |
| Jun 12, 26 | WILSON TROY EDWARD | sell | 10,800 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our PBYI coverage
Recent articles, reports, and earnings notes.
No research on PBYI yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate PBYI report →Puma: 3 Key Takeaways for Long-Term Investors
fool.com · Nov 8
Puma Biotechnology, Inc. (PBYI) Q3 2026 Earnings Call Prepared Remarks Transcript
seekingalpha.com · Nov 6
Puma Biotechnology Q3 Earnings Call Highlights
marketbeat.com · Nov 6
Puma Biotechnology Reports Third Quarter 2026 Financial Results
businesswire.com · Nov 5
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com · Nov 4
Puma Biotechnology to Host Conference Call to Discuss Third Quarter 2026 Financial Results
businesswire.com · Oct 22
Will Nerlynx Continue to Aid Puma Biotechnology's Top Line in Q3?
zacks.com · Oct 20
4 Breast Cancer Stocks to Watch During Breast Cancer Awareness Month
zacks.com · Oct 16
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.